	US 11,697,806 B2
	Polynucleotides, compositions, and methods for genome editing
Christian Dombrowski, Auburndale, MA (US); Jonathan Douglas Finn, Melrose, MA (US); Amy Madison Rhoden Smith, Durham, NC (US); and Seth C. Alexander, Medford, MA (US)
Assigned to Intellia Therapeutics, Inc., Cambridge, MA (US)
Filed by Intellia Therapeutics, Inc., Cambridge, MA (US)
Filed on Mar. 24, 2020, as Appl. No. 16/828,615.
Application 16/828,615 is a continuation of application No. PCT/US2018/053439, filed on Sep. 28, 2018.
Claims priority of provisional application 62/566,144, filed on Sep. 29, 2017.
Prior Publication US 2020/0354702 A1, Nov. 12, 2020
Int. Cl. C12N 15/11 (2006.01); C12N 9/22 (2006.01); A61K 9/51 (2006.01); C12N 15/88 (2006.01); C12N 15/85 (2006.01)

CPC C12N 9/22 (2013.01) [A61K 9/5123 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/85 (2013.01); C12N 15/88 (2013.01); C12N 2310/20 (2017.05); C12N 2320/32 (2013.01); C12N 2800/80 (2013.01)]

26 Claims

1. An mRNA comprising an open reading frame encoding an RNA-guided DNA-binding agent, wherein the open reading frame has an adenine content ranging from its minimum adenine content to 105% of the minimum adenine content, wherein the mRNA comprises a sequence with at least 98% identity to SEQ ID NO: 111, 114, or 117.